Tumor biomarkers and efficacy in patients treated with trastuzumab emtansine + pertuzumab versus standard of care in HER2-positive early breast cancer: an open-label, phase III study (KRISTINE)

1. de Haas, S.L.
2. Slamon, D.J.
3. Martin, M.
4. Press, M.F.
5. Lewis, G.D.
6. Lambertini, C.
7. Prat, A.
8. Lopez-Valverde, V.
9. Boulet, T.
10. Hurvitz, S.A.

Export

Export

×

MLA

modern-language-association

APA

apa

Chicago

chicago-fullnote-bibliography

Harvard

harvard-cite-them-right

Vancouver

vancouver-author-date

---

RIS BibTex

Export

×

This document cannot be exported because it belongs to another portal.

Full text

lock_openFull text externo

DOI: 10.1186/S13058-022-01587-Z GOOGLE SCHOLAR lock_openOpen access editor

Data source: Scopus